Saxagliptin/metformin extended release - AstraZeneca
Alternative Names: Kombiglyze XR; Metformin extended release/saxagliptin; Metformin XR/saxagliptin; Onglyza/metformin XR FDC; Saxagliptin/metformin XRLatest Information Update: 29 Nov 2019
At a glance
- Originator Bristol-Myers Squibb
- Developer AstraZeneca; BC Women's Hospital & Health Centre
- Class Adamantanes; Antihyperglycaemics; Biguanides; Cycloparaffins; Dipeptides; Insulin sensitisers; Nitriles; Organic bridged compounds; Piperidines; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Prediabetic state
Most Recent Events
- 29 Nov 2019 9277761, 3439306 : No update
- 28 Jul 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Brazil (PO, Tablet)
- 08 Feb 2019 Chemical structure information added